Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical pharmacogenetics in oncology: the paradigm of molecular targeted therapies.

Current pharmaceutical design - 1 Jan 2010

Mountzios Giannis, Sanoudou Despina, Syrigos Konstantinos N

Abstract excerpt

Even though treatment of several types of solid tumors has improved in the past few years with the introduction of molecular targeted agents in the therapeutic armamentarium of the medical oncologist, response rates to these agents are generally modest. Increasing evidence is now revealing that genetic factors are affecting patients' response to these therapeutic agents as well as the frequency and intensity of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy
Share to Molecular Targeted Therapy
Share to Neoplasm Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pharmacogenetics

Share to Precision Medicine

Share to Receptor, ErbB-2

Share to Receptors, Growth Factor

Share to Receptors, Vascular Endothelial Growth Factor

Source

Identifiers

PMID: 20459386
DOI: 10.2174/138161210791792859

Genes

EGFR
ERBB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical pharmacogenetics in oncology: the paradigm of molecular targeted therapies.PMID 20459386Read ↗

Pharmacogenetics of EGFR and VEGF inhibition.Semantic proximity Read ↗

Pharmacogenetics and pharmacogenomics of anticancer agents.Semantic proximity Read ↗

Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapySemantic proximity Read ↗

Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy.Semantic proximity Read ↗

Application of pharmacogenetics in oncologySemantic proximity Read ↗

Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.Semantic proximity Read ↗

Clinically relevant cancer biomarkers and pharmacogenetic assays.Semantic proximity Read ↗

Pharmacogenetics for severe adverse drug reactions induced by molecular-targeted therapy.Semantic proximity Read ↗

Cancer pharmacogenomics: DNA genotyping and gene expression profiling to identify molecular determinants of chemosensitivity.Semantic proximity Read ↗

Approaches to the discovery of pharmacogenomic markers in oncology: 2000-2010-2020.Semantic proximity Read ↗

Pharmacogenomic biomarkers for personalized cancer treatment.Semantic proximity Read ↗

Pharmacogenomics in breast cancer: current trends and future directions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.